A novel role for CD36 in VLDL-enhanced platelet activation

Diabetes

Volumn 52, Issue 5, 2003, Pages 1248-1255

  Englyst, Nicola A ^a   Taube, Janis M ^b   Aitman, Timothy J ^c   Baglin, Trevor P ^b   Byrne, Christopher D ^a,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; COLLAGEN; LIPOPROTEIN; MONOCLONAL ANTIBODY; THROMBOXANE A2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN CELL; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANTIGENS, CD; ANTIGENS, CD36; COLLAGEN; DIABETES MELLITUS, TYPE 2; HUMANS; LIPOPROTEINS, VLDL; PLATELET ACTIVATION; PLATELET AGGREGATION; REFERENCE VALUES; THROMBOXANE A2; TRIGLYCERIDES;

EID: 0242600800     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.5.1248     Document Type: Article

References (42)

1. Stern MP: Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 44:369-374, 1995
2. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219, 1996
3. Colwell JA, Halushka PV: Platelet function in diabetes mellitus. Br J Haematol 44:521-526, 1980
4. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ: Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128-138, 1990
5. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA: Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 17:433-438, 1991
6. de Man FH, Nieuwland R, van der Laarse A, Romijn F, Smelt AH, Gevers Leuven JA, Sturk A: Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 152:407-414, 2000
7. Schneider DJ, Tracy PB, Sobel BE: Acute coronary syndromes. 1. The platelet's role. Hosp Pract (Office Edition) 33:171-178, 184-185, 1998
8. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA: Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: homology with human CD36. J Biol Chem 268:17665-17668, 1993
9. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268:11811-11816, 1993
10. Nicholson AC, Frieda S, Pearce A, Silverstein RL: Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15:269-275, 1995
11. Puente Navazo MD, Daviet L, Ninio E, McGregor JL: Identification on human CD36 of a domain (155-183) implicated in binding oxidised low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol 16:1033-1039, 1996
12. Calvo D, Gómez-Coronado D, Suárez Y, Lasunción MA, Vega MA: Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 39:777-788, 1998
13. Pearce SF, Roy P, Nicholson AC, Hajjar DP, Febbraio M, Silverstein RL: Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain. J Biol Chem 273:34875-34881, 1998
14. Dutta-Roy AK, Gordon MJ, Campbell FM, Crosbie LC: Arachidonic acid uptake by human platelets is mediated by CD36. Platelets 7:291-295, 1996
15. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW: Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol (Online) 21:2011-2018, 2001
16. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St. Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J: Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21:76-83, 1999
17. Hevener AL, Reichart D, Janez A, Olefsky J: Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 50:2316-2322, 2001
18. Qi N, Kazdova L, Zidek V, Landa V, Kren V, Pershadsingh HA, St Lezin E, Abumrad NA, Pravenec M, Kurtz TW: Pharmacogenetic evidence that Cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 277:48501-48507, 2002
19. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM, Ibrahimi A, Abumrad NA, Qi N, Wang JM, St Lezin EM, Kurtz TW: Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 27:156-158, 2001
20. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, Matsuzawa Y: CD36 deficiency associated with insulin resistance. Lancet 357:686-687, 2001
21. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice [see comments]. J Clin Invest 105:1049-1056, 2000
22. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M: Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 161:65-74, 2002
23. Podrez EA, Batyreva E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Hoff HF, Salomon RG, Hazen SL: Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277:38503-38516, 2002
24. Podrez EA, Batyreva E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, Hazen SL: A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277:38517-38523, 2002
25. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL: Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105:1095-1108, 2000
26. Curtis BR, Aster RH: Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion 36:331-334, 1996
27. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, TweedieHardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 14; 1767-1774, 1994
28. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N: Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102:130-135, 1998
29. Rota S, McWilliam NA, Baglin TP, Byrne CD: Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 91:508-515, 1998
30. Taube J, McWilliam N, Luddington R, Byrne CD, Baglin T: Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins. Blood 93:3792-3797, 1999
31. Hackeng CM, Huigsloot M, Pladet MW, Nieuwenhuis HK, van Rijn HJ, Akkerman JW: Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling. Arterioscler Thromb Vasc Biol 19:239-247, 1999
32. Howard LM, Puente Navazo MD, McGregor JL: Identification of CD36reactive antibodies that bind an epitope encompassing animo acid residues 155-183. In Leucocyte Typing VI-Sixth International Workshop and Conference. Kishimoto T, Kikutani H, von dem Borne AEGK, Goyert SA, Mason DY, Miyasaka M, Moretta L, Okumura K, Shaw S, Springer TA, Sugamura K, Zola H, Eds. Kobe, Japan, Garland, 1996, p. 637-638
33. Cairns J, Cohen L, Colton T, DeMets DL, Deykin D, Friedman L, Greenwald P, Hutchison GB, Rosner B: Issues in the early termination of the aspirin component of the Physicians' Health Study: Data Monitoring Board of the Physicians' Health Study. Ann Epidemiol 1:395-405, 1991
34. Woods SE: Primary prevention of coronary heart disease in women. Should asymptomatic women 50 years of age take aspirin regularly? Arch Fam Med 3:361-364, 1994
35. Dutta Roy AK, Crosbie LC, Gordon MJ, Campbell FM: Platelet membrane glycoprotein IV (CD36) is involved in arachidonic acid induced-platelet aggregation (Abstract). Biochem Soc Trans 24:167S, 1996
36. Wieclawska B, Rozalski M, Trojanowski Z, Watala C: Modulators of intraplatelet calcium concentration affect the binding of thrombospondin to blood platelets in healthy donors and patients with type 2 diabetes mellitus. Eur J Haematol 66:396-403, 2001
37. Hajri T, Ibrahimi A, Coburn CT, Knapp FF, Kurtz T, Pravenec M, Abumrad NA: Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276:23661-23666, 2001
38. Beitz J, Mest HJ: Thromboxane A2 (TXA2) formation by washed human platelets under the influence of low and high density lipoproteins from healthy donors. Prostaglandins Leuko Med 23:303-309, 1986
39. Knorr M, Locher R, Vogt E, Vetter W, Block LH, Ferracin F, Lefkovits H, Pletscher A: Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Euro J Biochem 172:753-759, 1988
40. Beitz A, Perova N, Nikitina N, Beitz J, Scherbakova I, Giessler C, Mest HJ: Lipoproteins from normolipidemic and dyslipidemic subjects modify the thromboxane A2 generation by platelets in clotting human blood. Prostaglandins Leuko Essent Fatty Acids 48:475-479, 1993
41. Miller NE, Nordoy A: Effects of human plasma lipoproteins on platelet aggregation and platelet factor 3 activity in vitro. Atherosclerosis 28:181-186, 1977
42. Kehrel B, Kronenberg A, Rauterberg J, Niesing-Bresch D, Niehues U, Kardoeus J, Schwippert B, Tschope D, van de Loo J, Clemetson KJ: Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood 82:3364-3370, 1993